Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$3.04 USD
-0.03 (-0.98%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.03 -0.01 (-0.33%) 7:38 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Rocket Pharmaceuticals, Inc.'s return on equity, or ROE, is -64.92% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that RCKT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
RCKT 3.04 -0.03(-0.98%)
Will RCKT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RCKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCKT
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
RCKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
RCKT Stock Tanks on Patient Death in Danon Disease Study
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
Other News for RCKT
Biotech stocks rise following Prasad exit from FDA
Biotech stocks rise following Prasad exit from FDA
Rocket Pharmaceuticals (RCKT) Target Price Revised, Strategic Focus Shifted | RCKT Stock News
Rocket Pharmaceuticals (RCKT) Downgraded by B of A Securities | RCKT Stock News
Rocket Pharmaceuticals price target lowered by $1 at Canaccord, here's why